title: [Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie].
abstract: OBJECTIVE
  Given the scarcity of malignant phyllode tumours of the breast and the absence of consensus regarding their management justify the need for institutional retrospective evaluations of clinical practices.
  
  
  METHODS
  Retrospective study with central pathology review of the 25 consecutive patients treated at the Institut Curie (Paris, France) between 1969 and 2006 for non metastatic malignant phyllodes tumors of the breast. The median follow-up was 65 months (7-257 months).
  
  
  RESULTS
  Median age at diagnosis was 52 years (20-64 years). Breast surgery was conservative in five patients (20%). Surgical margins were wide (> 10mm), narrow, involved or unknown in respectively 17 (68%), three (12%), three (12%) and two (8%) patients. Median tumour size was 65 mm (12-250 mm). Adjuvant radiotherapy was delivered in seven (28%) patients (two patients, post-tumorectomy; five patients, post-mastectomy) and 13 patients (52%) received anthracycline-based adjuvant chemotherapy. Five-year overall survival rate was 91% (95% CI, 80-100%). Five patients (20%) developed distant metastases (one after chemotherapy) and three (12%) locoregional relapse (one after tumorectomy and unknown margin without radiotherapy, two after mastectomy and involved margins with radiotherapy).
  
  
  CONCLUSIONS
  Wide breast surgery (that can be conservative in selected patients) is the mainstay of the treatment of non metastatic malignant phyllodes tumors of the breast. To better determine the respective roles of adjuvant systemic treatment and radiotherapy, further clinical studies and the search for new prognostic and predictive factors remain necessary.
authors.affiliation: Département de radiothérapie oncologique, institut Curie, 26 rue d'Ulm, Paris cedex 05, France.
authors.forename: S
authors.initials: S
authors.lastname: Haberer
authors.forename: M
authors.initials: M
authors.lastname: Laé
authors.forename: V
authors.initials: V
authors.lastname: Seegers
authors.forename: J-Y
authors.initials: JY
authors.lastname: Pierga
authors.forename: R
authors.initials: R
authors.lastname: Salmon
authors.forename: Y M
authors.initials: YM
authors.lastname: Kirova
authors.forename: R
authors.initials: R
authors.lastname: Dendale
authors.forename: F
authors.initials: F
authors.lastname: Campana
authors.forename: F
authors.initials: F
authors.lastname: Reyal
authors.forename: O
authors.initials: O
authors.lastname: Miranda
authors.forename: A
authors.initials: A
authors.lastname: Fourquet
authors.forename: M-A
authors.initials: MA
authors.lastname: Bollet
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002173:Cancer Care Facilities; D017024:Chemotherapy, Adjuvant; D005260:Female; D005602:France; D006801:Humans; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D003557:Phyllodes Tumor / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult